Flotetuzumab
As of the edition of 20 October 2026, Flotetuzumab is an antibody: stopped in 2024; acts on CD3D, CD3E and CD3G and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 8, 4 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Skin and connective tissue; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 4 | 0 | 0 | 4 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| MacroGenics | Lead sponsor of trials |